4.5 Article

Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma

Journal

TRANSLATIONAL ONCOLOGY
Volume 15, Issue 1, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.tranon.2021.101251

Keywords

Glioblastoma; Organoids; Tumor microenvironments; Therapeutic resistance; Chemotherapy

Categories

Funding

  1. National Institutes of Health [NIH/NCATS CTSA KL2 TR0002547]
  2. American Brain Tumor Association Discovery Grant [DG1800016]
  3. American Cancer Society [IRG16-186-21]
  4. Center for Transformative Nanomedicine
  5. Peter D. Cristal Chair in Neurosurgery
  6. DC Austin Fund
  7. Arsouze Fund
  8. Kimble Family Foundation
  9. Ferry Family Foundation
  10. Gerald T. Kaufman Jr. Foundation
  11. [R21 CA256573]

Ask authors/readers for more resources

This study utilizes GBM organoid culture system to explore drug resistance, revealing diverse and spatial patterns of cell proliferation as well as relative insensitivity to conventional therapy, highlighting the potential of organoid cultures in understanding therapeutic mechanisms.
Background: Glioblastoma (GBM) is the most common primary brain tumor with a dismal prognosis. The inherent cellular diversity and interactions within tumor microenvironments represent significant challenges to effective treatment. Traditional culture methods such as adherent or sphere cultures may mask such complexities whereas three-dimensional (3D) organoid culture systems derived from patient cancer stem cells (CSCs) can preserve cellular complexity and microenvironments. The objective of this study was to determine if GBM organoids may offer a platform, complimentary to traditional sphere culture methods, to recapitulate patterns of clinical drug resistance arising from 3D growth. Methods: Adult and pediatric surgical specimens were collected and established as organoids. We created organoid microarrays and visualized bulk and spatial differences in cell proliferation using immunohistochemistry (IHC) staining, and cell cycle analysis by flow cytometry paired with 3D regional labeling. We tested the response of CSCs grown in each culture method to temozolomide, ibrutinib, lomustine, ruxolitinib, and radiotherapy. Results: GBM organoids showed diverse and spatially distinct proliferative cell niches and include heterogeneous populations of CSCs/non-CSCs (marked by SOX2) and cycling/senescent cells. Organoid cultures display a comparatively blunted response to current standard-of-care therapy (combination temozolomide and radiotherapy) that reflects what is seen in practice. Treatment of organoids with clinically relevant drugs showed general therapeutic resistance with drug- and patient-specific antiproliferative, apoptotic, and senescent effects, differing from those of matched sphere cultures. Conclusions: Therapeutic resistance in organoids appears to be driven by altered biological mechanisms rather than physical limitations of therapeutic access. GBM organoids may therefore offer a key technological approach to discover and understand resistance mechanisms of human cancer cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available